A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin’s lymphoma patients

References

• Bertino JR, Donohue DM, Simmons B, et al. The “induction” of dihydrofolic reductase activity in leukocytes and erythrocytes of patients treated with amethopterin. J Clin Invest. 1963;42:466–475.
   PubMed Web of Science ®Google Scholar
• Hertz R, Li MC, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med. 1956;93:361–366.
   PubMed Web of Science ®Google Scholar
• Holmboe L, Andersen AM, Morkrid L, et al. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73:106–114.
   PubMed Web of Science ®Google Scholar
• Tsurusawa M, Gosho M, Mori T, et al. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma. Pediatr Blood Cancer. 2015;62:279–284.
   PubMed Web of Science ®Google Scholar
• Mahoney DH, Jr., Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol. 1998;16:246–254.
   PubMed Web of Science ®Google Scholar
• Comandone A, Passera R, Boglione A, et al. High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. Acta Oncologica (Stockholm, Sweden). 2005;44:406–411.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21:4151–4156.
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489–4495.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24:3865–3870.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512–1520.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–1047.
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 1994;81:188–195.
   PubMed Web of Science ®Google Scholar
• Wolfrom C, Hartmann R, Fengler R, et al. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol. 1993;11:827–833.
   PubMed Web of Science ®Google Scholar
• Hegyi M, Gulacsi A, Csagoly E, et al. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma. J Cancer Res Clin Oncol. 2012;138:1697–1702.
   PubMed Web of Science ®Google Scholar
• Cohen IJ, Wolff JE. How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? Pediatr Blood Cancer. 2014;61:7–10.
   PubMed Web of Science ®Google Scholar
• Cai C, Chen X, Gong H. Interaction of anticancer drug methotrexate with nucleic acids analyzed by multi-spectroscopic method. Spectrochim Acta A Mol Biomol Spectrosc. 2009;72:46–49.
   PubMed Web of Science ®Google Scholar
• Martelli N, Mathieu O, Margueritte G, et al. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value? J Clin Pharm Ther. 2011;36:237–245.
   PubMed Web of Science ®Google Scholar
• Cohen IJ. Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX). Med Hypotheses. 2013;81:942–947.
   PubMed Web of Science ®Google Scholar
• Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146:489–503.
   PubMed Web of Science ®Google Scholar
• Skarby TV, Anderson H, Heldrup J, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia. 2006;20:1955–1962.
   PubMed Web of Science ®Google Scholar
• Sterba J, Dusek L, Demlova R, et al. Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: “folate overrescue” concept revisited. Clin Chem. 2006;52:692–700.
   PubMed Web of Science ®Google Scholar
• Wright KD, Panetta JC, Onar-Thomas A, et al. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol. 2015;75(1):27–35.
   PubMed Web of Science ®Google Scholar
• Ylinen E, Jahnukainen K, Saarinen-Pihkala UM, et al. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61:2199–2202.
   PubMed Web of Science ®Google Scholar
• Bertino JR. Clinical use of methotrexate–with emphasis on use of high doses. Cancer Treat Rep. 1981;65 Suppl 1:131–135.
   PubMedGoogle Scholar
• Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996;42:1322–1329.
   PubMed Web of Science ®Google Scholar
• Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238:787–793.
   PubMed Web of Science ®Google Scholar
• Seidel H, Andersen A, Kvaloy JT, et al. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables. Leuk Res. 2000;24:193–199.
   PubMed Web of Science ®Google Scholar
• Zelcer S, Kellick M, Wexler LH, et al. Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer. 2005;44:638–642.
   PubMed Web of Science ®Google Scholar
• Bokkerink JP, De Abreu RA, Bakker MA, et al. Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages. Biochem Pharmacol. 1988;37:2329–2338.
   PubMed Web of Science ®Google Scholar
• Bleyer WA. New vistas for leucovorin in cancer chemotherapy. Cancer. 1989;63:995–1007.
   PubMed Web of Science ®Google Scholar
• Plard C, Bressolle F, Fakhoury M, et al. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007;60:609–620.
   PubMedGoogle Scholar